Sutro Biopharma, Inc. - Common Stock, par value $0.001 per share (STRO)
CUSIP: 869367102
Q3 2025 13F Holders as of 30 Sep 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 16,182,923
- Total 13F shares
- 53,354,083
- Share change
- -2,176,965
- Total reported value
- $46,329,126
- Price per share
- $0.87
- Number of holders
- 84
- Value change
- -$1,641,183
- Number of buys
- 29
- Number of sells
- 53
Quarterly Holders Quick Answers
What is CUSIP 869367102?
CUSIP 869367102 identifies STRO - Sutro Biopharma, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 869367102:
Top shareholders of STRO - Sutro Biopharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
40%
|
6,488,324
|
$4,632,015 | — | 30 Jun 2025 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
5,088,099
|
$3,632,394 | — | 30 Jun 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
29%
|
4,732,243
|
$3,378,348 | — | 30 Jun 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
4.9%
from 13D/G
|
4,115,250
|
$2,938,288 | — | 30 Jun 2025 | |
| Velan Capital Investment Management LP |
13F
|
Company |
19%
|
3,060,000
|
$2,184,534 | — | 30 Jun 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
19%
|
3,042,238
|
$2,170,000 | — | 30 Jun 2025 | |
| Merck & Co., Inc. |
13F
|
Company |
17%
|
2,723,509
|
$1,944,313 | — | 30 Jun 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
16%
|
2,600,000
|
$1,856,140 | — | 30 Jun 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
16%
|
2,561,586
|
$1,828,716 | — | 30 Jun 2025 | |
| Eversept Partners, LP |
13F
|
Company |
14%
|
2,292,261
|
$1,636,445 | — | 30 Jun 2025 | |
| Samsara BioCapital, LLC |
13F
|
Company |
14%
|
2,196,814
|
$1,568,306 | — | 30 Jun 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
2.5%
from 13D/G
|
2,107,008
|
$1,504,193 | — | 30 Jun 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
12%
|
2,000,000
|
$1,427,800 | — | 30 Jun 2025 | |
| William J. Newell |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
768,806
mixed-class rows
|
$1,399,621 | — | 05 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
10%
|
1,618,884
|
$1,155,883 | — | 30 Jun 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
6.3%
|
1,012,716
|
$722,977 | — | 30 Jun 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
5.6%
|
913,197
|
$651,931 | — | 30 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
5%
|
816,915
|
$583,406 | — | 30 Jun 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
4.7%
|
752,722
|
$537,368 | — | 30 Jun 2025 | |
| Trevor Hallam |
3/4/5
|
Pres. Rsrch & Cf. Sctific Ofcr |
—
mixed-class rows
|
107,868
mixed-class rows
|
$507,563 | — | 14 Apr 2023 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
4.3%
|
688,850
|
$491,770 | — | 30 Jun 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
3.9%
|
628,473
|
$448,832 | — | 30 Jun 2025 | |
| CANTOR FITZGERALD, L. P. |
13F
|
Individual |
3.1%
|
500,000
|
$356,950 | — | 30 Jun 2025 | |
| Arturo Molina MD |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
127,236
mixed-class rows
|
$354,016 | — | 04 Mar 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
2.7%
|
437,079
|
$312,031 | — | 30 Jun 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
2.5%
|
405,748
|
$289,664 | — | 30 Jun 2025 | |
| Shabbir Anik |
3/4/5
|
Chief Technical Ops. Officer |
—
mixed-class rows
|
58,327
mixed-class rows
|
$274,452 | — | 03 Mar 2023 | |
| LPL Financial LLC |
13F
|
Company |
2.3%
|
370,748
|
$264,677 | — | 30 Jun 2025 | |
| Fisher Asset Management, LLC |
13F
|
Company |
2.2%
|
352,949
|
$251,970 | — | 30 Jun 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.1%
|
342,652
|
$244,619 | — | 30 Jun 2025 | |
| Venkatesh Srinivasan |
3/4/5
|
CHIEF TECH OP OFFICER |
—
mixed-class rows
|
254,436
mixed-class rows
|
$214,524 | — | 01 May 2025 | |
| Anne Elizabeth Borgman |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
115,264
mixed-class rows
|
$195,061 | — | 01 May 2025 | |
| Shay Capital LLC |
13F
|
Company |
1.6%
|
259,889
|
$185,535 | — | 30 Jun 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.6%
|
258,595
|
$184,611 | — | 30 Jun 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
1.5%
|
245,206
|
$175,053 | — | 30 Jun 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.4%
|
234,431
|
$166,446 | — | 30 Jun 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
1.4%
|
221,722
|
$159,000 | — | 30 Jun 2025 | |
| Edward C. Albini |
3/4/5
|
CFO AND SECRETARY |
0.99%
|
160,805
|
$141,508 | — | 15 May 2025 | |
| Linda A. Fitzpatrick |
3/4/5
|
CHIEF PEOPLE & COMM. OFFICER |
—
mixed-class rows
|
136,658
mixed-class rows
|
$134,667 | — | 01 May 2025 | |
| Barbara Leyman |
3/4/5
|
Chief Business Officer |
—
mixed-class rows
|
182,056
mixed-class rows
|
$127,443 | — | 08 Jul 2025 | |
| AJU IB Investment Co., Ltd. |
13F
|
Company |
1.1%
|
175,000
|
$124,933 | — | 30 Jun 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.1%
|
173,477
|
$123,845 | — | 30 Jun 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
1%
|
167,734
|
$119,745 | — | 30 Jun 2025 | |
| RBF Capital, LLC |
13F
|
Company |
0.99%
|
160,000
|
$114,224 | — | 30 Jun 2025 | |
| IEQ CAPITAL, LLC |
13F
|
Company |
0.76%
|
123,319
|
$88,037 | — | 30 Jun 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.71%
|
115,401
|
$82,385 | — | 30 Jun 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.71%
|
115,068
|
$82,147 | — | 30 Jun 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.65%
|
105,437
|
$75,272 | — | 30 Jun 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.64%
|
103,320
|
$73,760 | — | 30 Jun 2025 | |
| Nicki Vasquez |
3/4/5
|
CHIEF PORT. STRAT & ALNCE OFCR |
—
class O/S missing
|
14,279
|
$71,252 | — | 29 Jan 2024 |
Institutional Holders of Sutro Biopharma, Inc. - Common Stock, par value $0.001 per share (STRO) as of Q3 2025
As of 30 Sep 2025,
Sutro Biopharma, Inc. - Common Stock, par value $0.001 per share (STRO) was held by
84 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
53,354,083 shares.
The largest 10 holders included
SUVRETTA CAPITAL MANAGEMENT, LLC, Kynam Capital Management, LP, MILLENNIUM MANAGEMENT LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, Velan Capital Investment Management LP, TANG CAPITAL MANAGEMENT LLC, Merck & Co., Inc., Vestal Point Capital, LP, and Eversept Partners, LP.
This page lists
84
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
100
Q3 2025 holders
84
Holder diff
-16
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 Value $ | Q3 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.